Filing Flows

Filing Flows › Companies › Puma Biotechnology › Cash flow

Puma Biotechnology cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$1.6M in Q2 2026 · $41.2M over twelve months

Operating cash flow$1.6M
Free cash flow+$1.6M
Cash / net income0.2×
Cash conversion cycle88 days

Analysis

In Q2 2026, Puma Biotechnology generated $1.6M of operating cash flow. That is $12.4M less than in Q2 2025 ($14.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was $41.1M; the largest uses were net borrowing (+) / repaid (−) ($44.5M), other investing ($16.0M), other financing ($889K); besides operations, cash came from capital spending ($10K); the cash balance fell by $20.2M.

Operating cash flow was $1.6M against net income of $8.2M — 0.2× profit, less cash than reported earnings, worth checking against working capital. The largest differences: receivables −$7.7M, accrued liabilities +$6.7M, payables −$5.1M.

Its cash conversion cycle was 88 days (receivables 49 + inventory 80 − payables 41).

Free cash flow

Puma Biotechnology: free cash flow by quarterPuma Biotechnology: free cash flow by quarter$11.0MQ3 2024$15.6MQ4 2024$3.6MQ1 2025$14.1MQ2 2025$9.7MQ3 2025$14.5MQ4 2025$15.4MQ1 2026$1.6MQ2 2026
Operating cash flow less capital spending.
Puma Biotechnology: operating cash flow against capital spendingPuma Biotechnology: operating cash flow against capital spendingOperating cash flowCapital spending$11.0M$20KQ3 2024$15.6M$16KQ4 2024$3.6M$61KQ1 2025$14.1M$20KQ2 2025$9.7M$26KQ3 2025$14.4M−$36KQ4 2025$15.4M$0Q1 2026$1.6M$0Q2 2026
Latest (Q2 2026): Operating cash flow $1.6M, Capital spending $0.

Capital allocation, year by year

Puma Biotechnology: where the cash came from (up) and went (down), by fiscal yearPuma Biotechnology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow $20.6MFY2021: Net borrowing −$1.5M$20.6MFY2021FY2022: Operating cash flow −$15.8MFY2022FY2023: Operating cash flow $27.0MFY2023: Capital spending −$140K$27.0MFY2023FY2024: Operating cash flow $38.9MFY2024: Net borrowing −$33.3MFY2024: Shares issued $150KFY2024: Capital spending −$56K$39.1MFY2024FY2025: Operating cash flow $41.8MFY2025: Net borrowing −$44.4MFY2025: Shares issued $130KFY2025: Capital spending −$71K$41.9MFY2025
Over these 5 years operating cash flow totalled $113M; the largest uses were net borrowing ($79.3M) and operating cash flow ($15.8M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$93.9M
Debt$11.3M
Net cash$82.6M

Puma Biotechnology funds itself: free cash flow was $41.2M over the last twelve months, and $93.9M of cash and investments stands against $11.3M of debt.

Where the cash came from and went

Puma Biotechnology: sources (+) and uses (−) of cash, Q2 2026Puma Biotechnology: sources (+) and uses (−) of cash, Q2 2026Net borrowing (+) / repaid (−)−$11.1MOther investing$8.0MCash drawn (+) / kept (−)$1.7MOperating cash flow$1.6MOther financing−$223K
Puma Biotechnology: sources (+) and uses (−) of cash, TTM to Q2 2026Puma Biotechnology: sources (+) and uses (−) of cash, TTM to Q2 2026Net borrowing (+) / repaid (−)−$44.5MOperating cash flow$41.1MCash drawn (+) / kept (−)$20.2MOther investing−$16.0MOther financing−$889KCapital spending$10K

From profit to cash

Puma Biotechnology: net income to operating cash flow, Q2 2026Puma Biotechnology: net income to operating cash flow, Q2 2026Net income$8.2MDepreciation & amortization$2.5MStock-based pay$2.0MReceivables−$7.7MInventory−$4.6MPayables−$5.1MAccrued liabilities$6.7MPrepaid and other assets−$3KOperating cash flow$1.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202649804188
Q1 202680615785
Q4 202553302360
Q3 202550684574
Q2 202544644266
Q1 202556744981
Q4 202467384362
Q3 202447193333

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$1.6M—−$11.1M—$1.7M$1.6M
Q1 2026$15.4M—−$11.1M—−$6.6M$15.4M
Q4 2025$14.4M$36K−$11.1M—$23.9M$14.5M
Q3 2025$9.7M−$26K−$11.1M—$1.1M$9.7M
Q2 2025$14.1M−$20K−$11.1M—$8.4M$14.1M
Q1 2025$3.6M−$61K−$11.1M—$6.2M$3.6M
Q4 2024$15.6M−$16K−$11.1M—−$2.0M$15.6M
Q3 2024$11.0M−$20K−$11.1M$150K−$114K$11.0M

Puma Biotechnology: income statement and cash flow

Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%. The chart follows the revenue to costs, profit and cash.

Puma Biotechnology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.